Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension

• Status: Completed
• Trial end date: 2020-11-06

Summary

The study is intended to test the effectiveness and safety of Netarsudil / Latanoprost 0.02% / 0.005% Ophthalmic Solution, relative to GANFORT® for lowering of intraocular pressure (IOP) in patients with elevated intraocular pressure

• Phase: Phase 3

Details

• Lead Sponsor: Aerie Pharmaceuticals
• Treatments: Bimatoprost; Cloprostenol; Latanoprost; Ophthalmic Solutions; Pharmaceutical Solutions; Timolol